{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:15:56Z","timestamp":1792430156524,"version":"4.5.0"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,3,25]],"date-time":"2018-03-25T00:00:00Z","timestamp":1521936000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,3,25]],"date-time":"2018-03-25T00:00:00Z","timestamp":1521936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1111\/bjd.16156","type":"journal-article","created":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T11:21:23Z","timestamp":1511954483000},"page":"1083-1101","source":"Crossref","is-referenced-by-count":449,"title":["Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t"],"prefix":"10.1093","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-6993","authenticated-orcid":false,"given":"M.","family":"de Bruin-Weller","sequence":"first","affiliation":[{"name":"University Medical Center Utrecht; Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"University of L\u00fcbeck; L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.H.","family":"Smith","sequence":"additional","affiliation":[{"name":"St. John's Institute of Dermatology; London U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Reich","sequence":"additional","affiliation":[{"name":"Dermatologikum and TFS Research Institute; Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Cork","sequence":"additional","affiliation":[{"name":"Sheffield Dermatology Research; The University of Sheffield; Sheffield U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Radin","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.; Tarrytown NY U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.; Basking Ridge NJ U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Akinlade","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.; Tarrytown NY U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gadkari","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.; Tarrytown NY U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Eckert","sequence":"additional","affiliation":[{"name":"Sanofi; Chilly-Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hultsch","sequence":"additional","affiliation":[{"name":"Sanofi; Cambridge MA U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Chen","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.; Tarrytown NY U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pirozzi","sequence":"additional","affiliation":[{"name":"Sanofi; Bridgewater NJ U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.M.H.","family":"Graham","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.; Tarrytown NY U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Shumel","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.; Tarrytown NY U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,3,25]]},"reference":[{"key":"10.1111\/bjd.16156-BIB0001|bjd16156-cit-0001","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16156-BIB0002|bjd16156-cit-0002","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","article-title":"Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches","volume":"134","author":"Leung","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/bjd.16156-BIB0003|bjd16156-cit-0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2155-9899.1000110","article-title":"Th2 cytokines and atopic dermatitis","volume":"2","author":"Brandt","year":"2011","journal-title":"J Clin Cell Immunol"},{"key":"10.1111\/bjd.16156-BIB0004|bjd16156-cit-0004","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/bjd.16156-BIB0005|bjd16156-cit-0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-065X.2011.01027.x","article-title":"Atopic dermatitis: a disease of altered skin barrier and immune dysregulation","volume":"242","author":"Boguniewicz","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1111\/bjd.16156-BIB0006|bjd16156-cit-0006","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11882-015-0567-4","article-title":"The role of the skin microbiome in atopic dermatitis","volume":"15","author":"Williams","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1111\/bjd.16156-BIB0007|bjd16156-cit-0007","doi-asserted-by":"crossref","first-page":"pii","DOI":"10.1126\/scitranslmed.aah4680","article-title":"Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis","volume":"9","author":"Nakatsuji","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1111\/bjd.16156-BIB0008|bjd16156-cit-0008","doi-asserted-by":"crossref","first-page":"pii","DOI":"10.1126\/scitranslmed.aal4651","article-title":"Staphylococcus aureus and Staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis","volume":"9","author":"Byrd","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1111\/bjd.16156-BIB0009|bjd16156-cit-0009","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16156-BIB0010|bjd16156-cit-0010","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16156-BIB0011|bjd16156-cit-0011","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1468-3083.2012.04636.x","article-title":"Guidelines for treatment of atopic eczema (atopic dermatitis) part II","volume":"26","author":"Ring","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.16156-BIB0012|bjd16156-cit-0012","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1468-3083.2012.04635.x","article-title":"Guidelines for treatment of atopic eczema (atopic dermatitis) part I","volume":"26","author":"Ring","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.16156-BIB0013|bjd16156-cit-0013","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.alit.2016.12.003","article-title":"Japanese guidelines for atopic dermatitis 2017","volume":"66","author":"Katayama","year":"2017","journal-title":"Allergol Int"},{"key":"10.1111\/bjd.16156-BIB0014|bjd16156-cit-0014","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/1346-8138.13392","article-title":"Clinical practice guidelines for the management of atopic dermatitis 2016","volume":"43","author":"Saeki","year":"2016","journal-title":"J Dermatol"},{"key":"10.1111\/bjd.16156-BIB0015|bjd16156-cit-0015","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/jdv.13599","article-title":"ETFAD\/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients","volume":"30","author":"Wollenberg","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.16156-BIB0016|bjd16156-cit-0016","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s40629-016-0110-8","article-title":"S2k guideline on diagnosis and treatment of atopic dermatitis - short version","volume":"25","author":"Werfel","year":"2016","journal-title":"Allergo J Int"},{"key":"10.1111\/bjd.16156-BIB0017|bjd16156-cit-0017","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","article-title":"When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council","volume":"77","author":"Simpson","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16156-BIB0018|bjd16156-cit-0018","unstructured":"National Institute for Health and Care Excellence Atopic eczema in under 12s: diagnosis and management https:\/\/www.nice.org.uk\/guidance\/cg57\/resources\/atopic-eczema-in-under-12s-diagnosis-and-management-pdf-975512529349"},{"key":"10.1111\/bjd.16156-BIB0019|bjd16156-cit-0019","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1111\/bjd.16156-BIB0020|bjd16156-cit-0020","doi-asserted-by":"crossref","first-page":"e31465","DOI":"10.1371\/journal.pone.0031465","article-title":"Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of na\u00efve T cells into cytokine-producing mature T cells","volume":"7","author":"Tsuda","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1111\/bjd.16156-BIB0021|bjd16156-cit-0021","unstructured":"Sandimmune\u00ae [package insert] East Hanover, NJ Novartis Pharmaceuticals Corporation 2015"},{"key":"10.1111\/bjd.16156-BIB0022|bjd16156-cit-0022","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/all.12498","article-title":"Off-label prescriptions for atopic dermatitis in Europe","volume":"70","author":"Bieber","year":"2015","journal-title":"Allergy"},{"key":"10.1111\/bjd.16156-BIB0023|bjd16156-cit-0023","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/all.12339","article-title":"Systemic therapy for atopic dermatitis","volume":"69","author":"Simon","year":"2014","journal-title":"Allergy"},{"key":"10.1111\/bjd.16156-BIB0024|bjd16156-cit-0024","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2340\/00015555-2125","article-title":"Serum creatinine levels during and after long-term treatment with cyclosporin A in patients with severe atopic dermatitis","volume":"95","author":"Schaft","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/bjd.16156-BIB0025|bjd16156-cit-0025","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1080\/09546634.2016.1174765","article-title":"Addressing treatment challenges in atopic dermatitis with novel topical therapies","volume":"27","author":"Silverberg","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/bjd.16156-BIB0026|bjd16156-cit-0026","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaci.2013.07.049","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review","volume":"133","author":"Roekevisch","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/bjd.16156-BIB0027|bjd16156-cit-0027","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaip.2012.09.002","article-title":"Management of difficult-to-treat atopic dermatitis","volume":"1","author":"Arkwright","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1111\/bjd.16156-BIB0028|bjd16156-cit-0028","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2340\/00015555-0207","article-title":"Systemic treatment of severe atopic eczema: a systematic review","volume":"87","author":"Schmitt","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/bjd.16156-BIB0029|bjd16156-cit-0029","first-page":"802","article-title":"Long-term use of systemic treatments for moderate-to-severe atopic dermatitis in adults: a monocentric retrospective study","volume":"96","author":"V\u00e9die","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"Suppl. 48","key":"10.1111\/bjd.16156-BIB0030|bjd16156-cit-0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2133.1996.tb00704.x","article-title":"The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens","volume":"135","author":"Zonneveld","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16156-BIB0031|bjd16156-cit-0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-016-0170-1","article-title":"Systemic treatment of adult atopic dermatitis: a review","volume":"7","author":"Megna","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1111\/bjd.16156-BIB0032|bjd16156-cit-0032","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1468-3083.2006.01877.x","article-title":"Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis. Retrospective study of clinical and adverse events of cyclosporin A treatment","volume":"21","author":"Hijnen","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.16156-BIB0033|bjd16156-cit-0033","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/bjd.13730","article-title":"Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis","volume":"172","author":"Schaft","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16156-BIB0034|bjd16156-cit-0034","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2340\/00015555-2637","article-title":"Risk of non-melanoma skin cancer in patients with atopic dermatitis treated with oral immunosuppressive drugs","volume":"97","author":"Garritsen","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/bjd.16156-BIB0035|bjd16156-cit-0035","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2133.1994.tb02936.x","article-title":"Maintenance treatment with cyclosporin in atopic eczema","volume":"130","author":"Munro","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16156-BIB0036|bjd16156-cit-0036","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2133.1994.tb13111.x","article-title":"Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study","volume":"130","author":"Joost","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16156-BIB0037|bjd16156-cit-0037","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0140-6736(91)90134-B","article-title":"Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis","volume":"338","author":"Sowden","year":"1991","journal-title":"Lancet"},{"key":"10.1111\/bjd.16156-BIB0038|bjd16156-cit-0038","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2340\/0001555570323329","article-title":"Antipruritic effect of oral cyclosporin A in atopic dermatitis","volume":"70","author":"Wahlgren","year":"1990","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/bjd.16156-BIB0039|bjd16156-cit-0039","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jaad.2010.04.027","article-title":"Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial","volume":"64","author":"Haeck","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16156-BIB0040|bjd16156-cit-0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/bjd.16156-BIB0041|bjd16156-cit-0041","unstructured":"DUPIXENT\u00a9 [package insert] Regeneron Pharmaceuticals, Inc. Tarrytown, NY 2017"},{"key":"10.1111\/bjd.16156-BIB0042|bjd16156-cit-0042","unstructured":"Regeneron Pharmaceuticals, Inc Annex I. Summary of product characteristics Dupixent http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004390\/WC500236507.pdf"},{"key":"10.1111\/bjd.16156-BIB0043|bjd16156-cit-0043","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.16156-BIB0044|bjd16156-cit-0044","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"10.1111\/bjd.16156-BIB0045|bjd16156-cit-0045","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","article-title":"Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)","volume":"75","author":"Simpson","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16156-BIB0046|bjd16156-cit-0046","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.16156-BIB0047|bjd16156-cit-0047","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1111\/bjd.16156-BIB0048|bjd16156-cit-0048","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s13555-017-0181-6","article-title":"Dupilumab improves general health-related quality-of-life in patients with moderate-to-severe atopic dermatitis: pooled results from two randomized, controlled phase 3 clinical trials","volume":"7","author":"Simpson","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1111\/bjd.16156-BIB0049|bjd16156-cit-0049","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.16156-BIB0050|bjd16156-cit-0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1111\/bjd.16156-BIB0051|bjd16156-cit-0051","unstructured":"Regeneron Pharmaceuticals, Inc. Regeneron and Sanofi announce positive dupilumab topline results from phase 3 trial in uncontrolled persistent asthma http:\/\/files.shareholder.com\/downloads\/REGN\/5180646859x0x956274\/052CB4BF-935E-47E0-94D3-387BA464B9D8\/REGN_News_2017_9_11_General_Releases.pdf"},{"key":"10.1111\/bjd.16156-BIB0052|bjd16156-cit-0052","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1111\/bjd.16156-BIB0053|bjd16156-cit-0053","unstructured":"Hirano I Dellon ES Hamilton JD et al Dupilumab efficacy and safety in adult patients with active eosinophilic esophagitis: a randomized double-blind placebo-controlled phase 2 trial. World Congress of Gastroenterology at ACG"},{"key":"10.1111\/bjd.16156-BIB0054|bjd16156-cit-0054","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"key":"10.1111\/bjd.16156-BIB0055|bjd16156-cit-0055","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1398-9995.2011.02719.x","article-title":"EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference","volume":"67","author":"Schram","year":"2012","journal-title":"Allergy"},{"key":"10.1111\/bjd.16156-BIB0056|bjd16156-cit-0056","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-3999(01)00296-3","article-title":"The validity of the Hospital Anxiety and Depression Scale. An updated literature review","volume":"52","author":"Bjelland","year":"2002","journal-title":"J Psychosom Res"},{"key":"10.1111\/bjd.16156-BIB0057|bjd16156-cit-0057","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","article-title":"Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults","volume":"74","author":"Simpson","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16156-BIB0058|bjd16156-cit-0058","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/jid.2014.325","article-title":"Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study","volume":"135","author":"Silverberg","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.16156-BIB0059|bjd16156-cit-0059","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jaci.2012.10.041","article-title":"Mental health comorbidity in patients with atopic dermatitis","volume":"131","author":"Yaghmaie","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/bjd.16156-BIB0060|bjd16156-cit-0060","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s12325-017-0582-z","article-title":"Burden of atopic dermatitis in the United States: analysis of healthcare claims data in the commercial, Medicare, and Medi-Cal databases","volume":"34","author":"Shrestha","year":"2017","journal-title":"Adv Ther"},{"key":"10.1111\/bjd.16156-BIB0061|bjd16156-cit-0061","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s13555-017-0192-3","article-title":"Frequency and management of sleep disturbance in adults with atopic dermatitis: a systematic review","volume":"7","author":"Jeon","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"Suppl. S103","key":"10.1111\/bjd.16156-BIB0062|bjd16156-cit-0062","first-page":"47","article-title":"Efficacy and safety of dupilumab in adult patients with atopic dermatitis and a history of inadequate response, intolerance, or contraindication to cyclosporine: subgroup analysis from a 1-year trial","volume":"72","author":"Bruin-Weller","year":"2017","journal-title":"Allergy"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.16156","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.16156\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T10:16:45Z","timestamp":1693304205000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/178\/5\/1083\/6753031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,25]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.16156","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732206793.793542091","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.732206793.793541028","asserted-by":"object"}]},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3,25]]}}}